High-profile startup Wugen, with more than $200M in VC funding, begins clinical trial on cancer-fighting drug

St. Louis-based clinical-stage biotechnology startup Wugen, which has raised more than $200 million in venture, has dosed the first patient in a clinical trial for one of its cancer-fighting drug candidates.